Arbejdsmarkedets Tillaegspension Has $25.57 Million Stake in Gilead Sciences, Inc. $GILD

Arbejdsmarkedets Tillaegspension reduced its stake in shares of Gilead Sciences, Inc. (NASDAQ:GILD) by 5.9% in the 1st quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The fund owned 183,452 shares of the biopharmaceutical company’s stock after selling 11,412 shares during the period. Arbejdsmarkedets Tillaegspension’s holdings in Gilead Sciences were worth $25,568,000 at the end of the most recent quarter.

Several other hedge funds and other institutional investors have also recently bought and sold shares of GILD. Norges Bank acquired a new stake in shares of Gilead Sciences in the fourth quarter valued at about $2,617,152,000. Boston Partners acquired a new position in shares of Gilead Sciences in the fourth quarter worth approximately $517,808,000. Massachusetts Financial Services Co. MA boosted its holdings in Gilead Sciences by 3,763.8% in the fourth quarter. Massachusetts Financial Services Co. MA now owns 4,223,304 shares of the biopharmaceutical company’s stock valued at $518,368,000 after acquiring an additional 4,113,999 shares during the last quarter. Bank of America Corp DE boosted its holdings in Gilead Sciences by 15.2% in the fourth quarter. Bank of America Corp DE now owns 23,121,620 shares of the biopharmaceutical company’s stock valued at $2,837,948,000 after acquiring an additional 3,046,688 shares during the last quarter. Finally, Vanguard Group Inc. increased its position in Gilead Sciences by 1.8% during the 4th quarter. Vanguard Group Inc. now owns 121,097,336 shares of the biopharmaceutical company’s stock valued at $14,863,487,000 after purchasing an additional 2,113,692 shares during the period. 83.67% of the stock is owned by institutional investors and hedge funds.

Insider Activity

In other Gilead Sciences news, insider Johanna Mercier sold 3,000 shares of the stock in a transaction that occurred on Monday, June 15th. The stock was sold at an average price of $123.92, for a total value of $371,760.00. Following the transaction, the insider owned 124,234 shares in the company, valued at approximately $15,395,077.28. This represents a 2.36% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, CFO Andrew D. Dickinson sold 3,000 shares of the firm’s stock in a transaction that occurred on Monday, June 15th. The shares were sold at an average price of $125.40, for a total value of $376,200.00. Following the completion of the sale, the chief financial officer directly owned 171,646 shares of the company’s stock, valued at $21,524,408.40. This trade represents a 1.72% decrease in their position. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders sold a total of 83,000 shares of company stock worth $10,824,500 in the last three months. Company insiders own 0.30% of the company’s stock.

Gilead Sciences Stock Performance

Shares of GILD stock opened at $129.83 on Monday. The firm has a 50 day moving average of $129.78 and a 200-day moving average of $135.03. The company has a market cap of $161.19 billion, a price-to-earnings ratio of 17.69 and a beta of 0.32. The company has a quick ratio of 1.77, a current ratio of 1.97 and a debt-to-equity ratio of 0.89. Gilead Sciences, Inc. has a 52 week low of $107.75 and a 52 week high of $157.29.

Gilead Sciences (NASDAQ:GILD) last released its earnings results on Thursday, May 7th. The biopharmaceutical company reported $2.03 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $1.91 by $0.12. The company had revenue of $6.96 billion for the quarter, compared to the consensus estimate of $6.91 billion. Gilead Sciences had a net margin of 30.99% and a return on equity of 48.19%. Gilead Sciences’s quarterly revenue was up 4.4% compared to the same quarter last year. During the same quarter in the previous year, the company earned $1.81 EPS. Gilead Sciences has set its FY 2026 guidance at -1.050–0.650 EPS. On average, equities analysts forecast that Gilead Sciences, Inc. will post -0.8 earnings per share for the current year.

Gilead Sciences Announces Dividend

The business also recently disclosed a quarterly dividend, which was paid on Monday, June 29th. Stockholders of record on Monday, June 15th were given a dividend of $0.82 per share. This represents a $3.28 dividend on an annualized basis and a dividend yield of 2.5%. The ex-dividend date of this dividend was Monday, June 15th. Gilead Sciences’s dividend payout ratio is 44.69%.

Wall Street Analysts Forecast Growth

GILD has been the subject of several analyst reports. Wall Street Zen upgraded shares of Gilead Sciences from a “hold” rating to a “buy” rating in a report on Sunday. Truist Financial decreased their price objective on shares of Gilead Sciences from $157.00 to $156.00 and set a “buy” rating for the company in a research report on Tuesday, July 7th. The Goldman Sachs Group lifted their target price on shares of Gilead Sciences from $125.00 to $130.00 and gave the stock a “neutral” rating in a research note on Friday, April 17th. Citigroup boosted their target price on shares of Gilead Sciences from $156.00 to $165.00 and gave the company a “buy” rating in a report on Monday, April 13th. Finally, HSBC raised shares of Gilead Sciences from a “hold” rating to a “buy” rating and upped their price target for the company from $133.00 to $155.00 in a research report on Monday, July 6th. Twenty-six analysts have rated the stock with a Buy rating and three have issued a Hold rating to the company’s stock. According to MarketBeat, Gilead Sciences currently has an average rating of “Moderate Buy” and a consensus target price of $159.04.

Gilead Sciences Company Profile

Gilead Sciences, Inc, founded in 1987 and headquartered in Foster City, California, is a biopharmaceutical company focused on the discovery, development and commercialization of medicines in areas of high unmet medical need. The company initially built its reputation in antiviral therapies and has since expanded into oncology, cell therapy and inflammatory diseases. Gilead operates a global research and commercial organization, conducting clinical development and selling medicines in markets around the world.

Gilead’s product portfolio is anchored by antiviral therapies for HIV and viral hepatitis.